Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rienk Offringa

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Science (New York, N.Y.)|October 7, 2006
Cancer. Cancer immunotherapy is more than a numbers gameRienk Offringa
Current Opinion in Immunology|March 20, 2009
Antigen choice in adoptive T-cell therapy of cancerRienk Offringa
Current Opinion in Immunology|March 16, 2005
Tumour immunology exploitation of the weapon of immune destruction for cancer therapy: taking aim before firingRienk Offringa
Cell Research|June 3, 2015
Cancer immunotherapy: exploiting neoepitopesMichael Platten, Rienk Offringa
Expert Reviews in Molecular Medicine|February 28, 2004
Anti-p53-directed immunotherapy of malignant diseaseMatthias Theobald, Rienk Offringa
Cell Stress|October 7, 2020
Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapyDaniel Baumann, Rienk Offringa
Cancer Cell|September 17, 2015
Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG FrameworkRienk Offringa, Martin J Glennie
The Journal of Pathology|August 30, 2016
Next-generation TCR sequencing - a tool to understand T-cell infiltration in human cancersIsabel Poschke, Michael Flossdorf, Rienk Offringa
Blood|June 7, 2006
Does the serpin PI-9 protect tumor cells?Michael Bots, Rienk Offringa, Jan Paul Medema
Nature Reviews. Drug Discovery|August 18, 2022
The expanding role for small molecules in immuno-oncologyRienk Offringa, Lisa Kötzner, Bayard Huck, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Science (New York, N.Y.)|October 7, 2006
Cancer. Cancer immunotherapy is more than a numbers gameRienk Offringa
Current Opinion in Immunology|March 20, 2009
Antigen choice in adoptive T-cell therapy of cancerRienk Offringa
Current Opinion in Immunology|March 16, 2005
Tumour immunology exploitation of the weapon of immune destruction for cancer therapy: taking aim before firingRienk Offringa
Cell Research|June 3, 2015
Cancer immunotherapy: exploiting neoepitopesMichael Platten, Rienk Offringa
Expert Reviews in Molecular Medicine|February 28, 2004
Anti-p53-directed immunotherapy of malignant diseaseMatthias Theobald, Rienk Offringa
Cell Stress|October 7, 2020
Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapyDaniel Baumann, Rienk Offringa
Cancer Cell|September 17, 2015
Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG FrameworkRienk Offringa, Martin J Glennie
The Journal of Pathology|August 30, 2016
Next-generation TCR sequencing - a tool to understand T-cell infiltration in human cancersIsabel Poschke, Michael Flossdorf, Rienk Offringa
Blood|June 7, 2006
Does the serpin PI-9 protect tumor cells?Michael Bots, Rienk Offringa, Jan Paul Medema
Nature Reviews. Drug Discovery|August 18, 2022
The expanding role for small molecules in immuno-oncologyRienk Offringa, Lisa Kötzner, Bayard Huck, et al.
Pageof 12